| Original language | English (US) |
|---|---|
| Pages (from-to) | 13-15 |
| Number of pages | 3 |
| Journal | Oncotarget |
| Volume | 13 |
| DOIs | |
| State | Published - 2022 |
Keywords
- Checkpoint
- Hyperprogression
- Immunotherapy
- Mouse model
- PD-1
ASJC Scopus subject areas
- Oncology
MD Anderson CCSG core facilities
- Clinical and Translational Research Center
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Oncotarget, Vol. 13, 2022, p. 13-15.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Unravelling the underpinnings of hyperprogression and immunotherapy
T2 - back to the bench
AU - Subbiah, Vivek
AU - Kurzrock, Razelle
N1 - Funding Information: Vivek Subbiah (VS) is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center. VS acknowledges support of The Jacquelyn A. Brady Fund. VS is supported by National Institutes of Health grant R01CA242845. MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, 1U01 CA180964, NCATS Grant UL1 TR000371 (Center for Clinical and Translational Sciences), and the MD Anderson Cancer Center Support Grant (P30 CA016672). Figure 1 was created with https:// biorender.com. Funding Information: VS reports a grant and advisory board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the study. VS also reports research grants from Roche/ Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune; an advisory board/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay therapeutics, Roche and Medimmune; travel funds from Pharmamar, Incyte, ASCO, and ESMO; other support from Medscape; all outside the submitted work. RK has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch.
PY - 2022
Y1 - 2022
KW - Checkpoint
KW - Hyperprogression
KW - Immunotherapy
KW - Mouse model
KW - PD-1
UR - http://www.scopus.com/inward/record.url?scp=85125711902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125711902&partnerID=8YFLogxK
U2 - 10.18632/ONCOTARGET.28098
DO - 10.18632/ONCOTARGET.28098
M3 - Review article
C2 - 35018215
AN - SCOPUS:85125711902
SN - 1949-2553
VL - 13
SP - 13
EP - 15
JO - Oncotarget
JF - Oncotarget
ER -